A team of cancer researchers, led by the University of Houston, has discovered a new subset of T cells that may improve the outcome for patients treated with T-cell therapies. T cell-based ...

CLN-049’s anti-leukaemic impact was observed regardless of FLT3 status, which is the most commonly mutated protein in AML.

The results of the study could improve immunotherapy treatment for patients with colorectal and other barrier-tissue cancers.

Scientists at the University College London (UCL) have developed a novel therapy that helps treat patients with T cell acute ...

Glioblastoma (GBM), an aggressive form of cancer that grows in the brain or spinal cord, occurs at an incidence rate of about 3/100,000 persons in the United States. Effective treatments remain ...

ALLO-316 targets CD70, a surface antigen highly expressed in renal cell carcinoma, offering potential for heavily pretreated patients. The FDA's designation is based on early evidence from the phase 1 ...

Bicistronic CD19/CD22-directed CAR-T cell therapy achieved high remission rates and durable responses in pediatric B-ALL patients. One-year EFS and OS rates were 75.5% and 93.5%, respectively, with ...

Percentage of γδ T cells increased in multiple myeloma patients. (A) gating for γδ T cells in multiple myeloma patients; (B) gating for γδ T cells in healthy controls. - Increased CD8⁺ T cells (P < ...